Arvinas (NASDAQ:ARVN – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Institutional and Insider Ownership
95.2% of Arvinas shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Arvinas and Monte Rosa Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arvinas | $262.60 million | 2.04 | -$80.80 million | $0.10 | 82.90 |
| Monte Rosa Therapeutics | $123.67 million | 8.37 | -$38.63 million | ($1.76) | -6.89 |
Monte Rosa Therapeutics has lower revenue, but higher earnings than Arvinas. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Arvinas has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Profitability
This table compares Arvinas and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arvinas | 2.94% | 1.91% | 1.29% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Arvinas and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arvinas | 2 | 4 | 5 | 0 | 2.27 |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
Arvinas presently has a consensus price target of $14.17, suggesting a potential upside of 70.89%. Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 134.95%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Arvinas.
Summary
Arvinas beats Monte Rosa Therapeutics on 9 of the 15 factors compared between the two stocks.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
